The purpose of this study:(1) Development of a new risk classification model for childhood medulloblastoma. (2) Evaluation and improvement of existing individualized treatment protocols.
Age 0.5-18 years (except neonates).
Pathologically confirmed medulloblastoma.
Not having received any other relevant treatment before surgery.
Completion of enhanced MRI of the head and spinal cord.
Patients who have recently received other drugs or radiation therapy.
Patients suffering from acute or chronic infectious diseases
Patients suffering from neurological or psychiatric diseases or mental disorders that cannot be easily controlled, or poor compliance.
Patients who cannot receive enhanced MRI scans.
Beijing Tiantan Hospital
Lead sponsor
Beijing Neurosurgical Institute
Collaborator
Beijing Children's Hospital
Collaborator
Beijing Shijitan Hospital, Capital Medical University
Collaborator
Xuanwu Hospital, Beijing
Collaborator
Peking University Third Hospital
Collaborator